Tandem Investment Partners LLC Has $971,000 Stake in Johnson & Johnson $JNJ

Tandem Investment Partners LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 12.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,357 shares of the company’s stock after purchasing an additional 707 shares during the period. Tandem Investment Partners LLC’s holdings in Johnson & Johnson were worth $971,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in JNJ. Highline Wealth Partners LLC raised its holdings in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the first quarter worth about $48,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson during the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson in the 1st quarter valued at about $52,000. Institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $188.23 on Tuesday. The business’s 50-day moving average price is $176.62 and its 200-day moving average price is $163.00. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $189.92. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $453.32 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the company earned $2.82 EPS. The firm’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JNJ. UBS Group set a $198.00 price target on shares of Johnson & Johnson in a research report on Friday. Bank of America raised their target price on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a report on Friday. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday. Finally, JPMorgan Chase & Co. boosted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $189.12.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.